Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study.
2020
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
7
References
0
Citations
NaN
KQI